Xerostomia is defined as the subjective sensation of dry mouth and hyposalivation as the objective reduction of salivary flow and changes in its composition. 8 Among the main causes of salivary dysfunction are drugs, ageing, radiotherapy, chemotherapy and systemic diseases such as rheumatological, endocrine, neurological, genetic, metabolic and infectious disorders. 5 Several drugs may induce hyposalivation and xerostomia. Irrespective of the nature of drugs, the number of daily medications linearly reduces salivary secretion. 9 Among the drugs associated with salivary hypofunction stand out tricyclic antidepressants, antihypertensive, diuretic and antispasmodic drugs. 10, 11 Another important cause of salivary changes is head and neck radiotherapy. Major salivary glands are often involved in the radiation fields because they are in the vicinity of the primary tumours and lymphatic chains of those regions. As a consequence of radiotherapy, there is a process of glandular degeneration, resulting in hyposalivation and xerostomia. 12 The severity of salivary dysfunction is related to the dose of radiation used, the volume of tissue irradiated and the patient's individual response. 12, 13 Qualitative and quantitative salivary dysfunctions cause a negative impact on the quality of life and predispose the individual to alterations in the oral mucosa and in the teeth. 1, 4, 5 There is impairment of oral functions, resulting in dysgeusia, dysphagia and dysarthria. The oral mucosa becomes dry and atrophic, giving rise to frequent traumas. 5, 8 There are also alterations in oral microflora and salivary composition, and there may be progression of dental caries, gingivitis, halitosis, mucositis, oropharyngeal candidiasis, maladaptation of dentures, bacterial sialadenitis among others. 14, 15 Considering the importance of saliva for the maintenance of oral and general homoeostasis, this study is an updated approach of the main therapeutic options to salivary hypofunction.
| MATERIAL AND ME THODS
A MEDLINE/PubMed search was conducted using the terms "Xerostomia" AND, "Saliva Artificial" OR, "Citric Acid" OR, "Malic Acid" OR, "Chewing Gum" OR, "Acupuncture" OR, "Pilocarpine" OR "Bethanechol" OR "Cevimeline" OR "Hyperbaric Oxygen Therapy" OR "Stem Cell Therapy" OR, "Genetic Therapy" and their Mesh Terms.
Articles published in the English language from 1995 to 2017 were selected and reviewed. Suitable references from these articles were also reviewed. The search was limited to controlled clinical trials.
After the initial search, the exclusion of articles was carried out by reading the titles and abstracts. If there was insufficient information provided in the abstract, the authors reviewed the full article before include it. Data extraction was then completed. The following data were collected: sample, cause of salivary hypofunction, intervention (including dosage and follow-up) and outcome. For gene therapy, there was only one clinical trial and, although it was not controlled, the study was included. The search strategy and the flow diagram of article selection are shown in Figure 1 .
For the item stem cell therapy, there were no clinical trials, so
we selected three studies in animal models. These articles are not described in Figure 1 .
| RE SULTS
In this study, we classified the treatments for xerostomia into symptomatic, topical or systemic stimulants and regenerative. 8, 16, 17 We selected 25 clinical trials, among them, 24 randomised controlled trials. Table 1 summarises therapies with strong evidence of a beneficial effect on the management of salivary dysfunctions (pilocarpine and cevimeline). Table 2 shows promising evidence (acupuncture and gene therapy), and Table 3 presents therapies with weak evidence (salivary substitutes, chewing gum, malic and citric acids, bethanechol and hyperbaric oxygen therapy) of a positive effect on xerostomia and hyposalivation.
| Symptomatic treatments
The most commonly used symptomatic approaches are increased fluid intake and the use of salivary substitutes. These interventions consist in the relief of xerostomia by the use of topical agents that maintain the lubrication of the mucosa.
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Oral rehydrating agents, also known as salivary substitutes, act directly on the surface of the mucosa, but have no effect on salivary stimulation. Salivary substitutes such as animal mucin, carboxymethyl cellulose (CMC), hydroxypropyl methylcellulose (HPMC), hydroxyethylcellulose (HEC) and polyglycerylmethacrylate (PGM) have been used and some have components with similar properties to the glycoproteins and antibacterial agents present in saliva. 19, 20 Gels containing HPMC, given to irradiated participants, showed a potential reduction in oral discomfort caused by xerostomia. 21 In this study, we selected three controlled clinical trials investigating the effect of salivary substitutes on xerostomia. In addition, oral xanthan gum, mucin, linseed extract and aloe vera, all found in mouthwashes, sprays or gels can be used as oral rehydrating agents. 23 Each patient adapts to the presentation of the substance according to their daily routine. Jellema et al 24 evaluated, in a double-blind controlled study, the salivary substitute xanthan gum (Xialine ® ) in 30 participants with radiation-induced xerostomia.
The substance was used for 1 week, at least four times a day, and the washout period between substance use and placebo was 1 week.
No differences were observed between xanthan gum and placebo in relation to xerostomia, salivary viscosity or influence on swallowing.
In a single-blind and crossover study, Alpöz et al 25 were instructed to use the substances six times a day for 14 days. No statistically significant differences were noted between the groups with regard to burning tongue, taste and waking up at night to sip water. However, the patients preferred xanthan gum at the end of the study.
In the three studies, the number of participants was low. Shahdad et al 22 compared two different salivary substitutes and did not include a group using placebo. Jellema et al 24 and Alpöz et al 25 did not find differences between xanthan gum and placebo. Therefore, there is no evidence that hydroxyethyl cellulose, polyglycerylmethacrylate and xanthan gum have effect on reducing the symptoms of xerostomia. As they are easily removed from the mouth by swallowing, salivary substitutes have a short-term effect and some are contraindicated in dentate patients due to tooth enamel demineralisation they might cause. 
| Salivary stimulants

| Citric acid and malic acid
The citric acid action and malic acid action are based on its dissociation in H+, acidifying the oral environment, which generates stimulation of salivary secretion to dilute its concentration in the oral cavity. 23 Three randomised and controlled clinical trials on citric acid and malic acid were selected in this study.
According to Femiano et al, 26 when there is still functional salivary tissue, one of the alternatives for xerostomia and hyposalivation is 3% citric acid. This is a natural sialagogue, which stimulates the taste buds through efferent parasympathetic pathways, inducing increased salivary secretion. Citric acid (3%) was administered by 5 mL rinse for 30 seconds, four times a day for 30 days. The sample consisted of 54 participants with drug-induced xerostomia. There Full-text analysis n = 25
was immediate and significant improvement in dry mouth symptoms 15 minutes after rinsing. Citric acid provided a longer lasting beneficial effect in relief of xerostomia compared to artificial saliva.
This effect may be a consequence of simultaneous stimulation of the major and minor salivary glands. 44 participants Sjögren's syndrome Cevimeline There was no significant difference between groups cevimeline and placebo in stimulated whole saliva (P = .489) and stimulated parotid saliva (P = .073)
Chambers et al 48 
participants Head and neck radiotherapy
Cevimeline There was a significant difference in the unstimulated salivary flow for the cevimeline-treated group when compared to the placebo group (P = .0093 in the first phase and P = .0215 in the second phase of the study). On the other hand, no significant difference was found regarding stimulated salivary flow (P > .05)
Although citric acid and malic acid have shown improvement in xerostomia, the samples of the studies were small and the follow-up times were short. Moreover, the use of acidic substances as salivary stimulants may increase the risk of dental hypersensitivity and erosion, and dental caries. With the presence of xylitol and fluorides in acid salivary stimulants, the decrease in salivary pH levels does not exceed the limit of 5.5-critical level for hydroxyapatite. 
| Chewing gum
Sugar-free chewing gums, containing xylitol, are used to stimulate salivary flow and promote transient xerostomia relief by the capability to stimulate residual glandular tissue. 20 In addition, they may inhibit the development of cariogenic bacteria, reducing the amount of caries. They increase the salivary volume by the mechanical and taste receptors stimulation, and they are widely used because they do not cause side effects. 29, 30 On the other hand, patients with total dentures may have reduced masticatory capacity and may not be able to use this method. 5 Two controlled clinical trials were selected in this study. Based on both studies, there is no evidence about the positive effect of chewing gum on xerostomia and hyposalivation. In the study of Kaae et al, 30 performed in head and neck irradiated participants, there was an important bias, once the control group consisted of healthy participants, who did not show xerostomia.
| Acupuncture
It is assumed that the possible mechanism of action of acupuncture in the treatment of patients with xerostomia/hyposalivation is based on stimulation of the autonomic nervous system through the afferent neurons. There is an increase in the activity of the parasympathetic nervous system, which increases the release of specific neuropeptides. 31 These neuropeptides possibly have numerous trophic effects, which include increased blood flow in the salivary Acupuncture Acupuncture given concurrently with radiotherapy significantly prevented xerostomia. Xerostomia scores were significantly lower for acupuncture than for controls (P = .003 at week 3, all other P < .0001). The saliva flow was significantly higher in the acupuncture group at weeks 7 (unstimulated salivary flow, P < .0001; stimulated salivary flow, P = .002) and 11 (unstimulated salivary flow, P < .02; stimulated salivary flow, P < .03) and at 6 mo (stimulated salivary flow, P < .003) Bethanechol Participants in the placebo group had significantly higher degrees of xerostomia when compared to those receiving bethanechol (P < .0041). Bethanechol also preserved unstimulated and stimulated salivary flow compared to placebo (P = .008; P = .005, respectively)
Teguh et al 65 
participants Head and neck radiotherapy
Hyperbaric oxygen therapy A significant difference was found in the treated group when compared to the untreated group in relation to salivary consistency and xerostomia (P = .01 and P = .009, respectively)
glands, elevated acinar cell metabolism and salivary production, and possibly tissue regeneration. 31 Four randomised and controlled tri- trial with 86 participants with nasopharyngeal carcinoma was conducted comparing acupuncture to standard care. Acupuncture was performed three times a week on the same days of radiotherapy.
Participants were followed for 6 months after the end of radiotherapy. Xerostomia scores were significantly lower for acupuncture group compared to the control. Unstimulated and stimulated salivary flow was greater in the acupuncture group at weeks seven and 11 and at 6 months.
Double-blind studies with this technique are rare, possibly for ethical reason. In the study of Blom et al, 31 for example, superficial acupuncture was employed in the control group, which represented an important bias. Despite this, the studies suggest the efficacy of acupuncture in combating xerostomia.
| Pilocarpine
Pilocarpine is a parasympathomimetic drug, agonist for the muscarinic receptors on the surface of the salivary cells. It acts as a stimulant of secretion of exocrine glands and participates in the contraction of the smooth muscle, gastrointestinal tract, urinary tract, gallbladder, bile ducts and bronchi. 5, 20, 35 The administration of pilocarpine to stimulate residual glandular function after head and neck radiotherapy is widely accepted, but the effect persists only while the drug is administered. Part of its effect in patients with postradiotherapy xerostomia is attributed to the stimulation of the minor salivary glands of the palate, which have been shown to be resistant to radiation. 18 In this study, we selected five randomised and controlled clinical trials on the effect of pilocarpine on xerostomia and hyposalivation.
In a randomised double-blind clinical study, Taweechaisupapong The studies indicate that pilocarpine may be an alternative to decrease xerostomia and salivary hypofunction. Administration of 5-mg pilocarpine tablets was well tolerated and produced improvement in radiotherapy-induced xerostomia and in patients with Sjögren's syndrome. However, as it is a cholinergic drug, patients can present side effects such as nausea, lacrimation, sweating, frequent urination, rhinitis, low-intensity headache and gastrointestinal disturbs. 
| Bethanechol
Bethanechol is a carbamate ester resistant to the action of cholinesterase and most of its action is linked to activity at the M3 muscarinic receptor. 5, 20 The effectiveness of this drug in reducing xerostomia has been tested. Two randomised controlled clinical trials on the effect of bethanechol on salivary dysfunctions were included. 
| Cevimeline
Cevimeline is an analogue of acetylcholine, with high bond to M3 muscarinic receptors located in the epithelium of the lacrimal and salivary glands. 44, 45 In this study, four controlled randomised clinical trials were selected to analyse the efficacy of cevimeline on salivary dysfunction. Even though cevimeline increases saliva production, the drugresponse mechanism is still unknown. Suzuki et al, 44 in a crossover and controlled study, administered 30 mg of cevimeline to healthy participants to evaluate the effects of the drug on the salivary and plasma levels of the neuropeptides substance-P (SP), calcitonin gene-related peptide (CGRP) and vasoactive intestinal polypeptide (VIP). Salivary and serum samples were obtained prior to drug administration, then after 30, 60, 90, 120, 180 and 240 minutes. There was a significant increase in salivary volume between 90, 180 and 240 minutes after administration of cevimeline when compared to placebo. There was an increase in salivary SP polypeptide levels, which acts as a vasodilator and increases blood flow, which may indicate an association between this substance and the elevation of salivary secretion stimulated by the drug. On the other hand, there was no increase in plasma levels of the other peptides studied.
Use of 30 mg of cevimeline three times daily provides an option for the treatment of xerostomia in Sjögren's syndrome and in irradiated patients.
| Regenerative therapies
| Stem cell therapy
The cells that constitute the salivary glands have constant basal proliferative activity, suggesting that the glandular epithelium maintains its regenerative capacity. One of the theories explaining such proliferative activity describes cell differentiation from stem cells, which are present in the intercalated ducts. The extraction of mesenchymal stem cells from the parotid and submandibular glands has been performed in some studies and those have the capacity to differentiate both in acinar and ductal cells. 49 In addition to the cells of the glandular epithelium, cells of mesenchymal origin can be extracted from the bone marrow. They may be cultured in vitro to differentiate and then to be implanted in salivary glands damaged by radiotherapy. [50] [51] [52] Adipose tissue can also be used to extract multipotent cells. Such cells are able to differentiate into strains of osteogenic, adipogenic, myogenic and chondrogenic tissues. It is easy to obtain those cells through aspiration, which causes little discomfort to the donor. 49, 53 Once it is a recent field of research, studies addressing stem cell regenerative therapy in salivary glands are scarce and performed in animal models. Three studies addressing stem cell therapy in salivary glands of rats submitted to ionising radiation are described below. Although many questions remain to be answered, significant progress has been made with respect to stem cell and their potential to attenuate salivary gland dysfunction. In the near future, cell-based therapies may restore function of radiation-damaged salivary gland. 
| Gene therapy
Gene therapy may become a therapeutic option for radiationinduced salivary hypofunction. of new capillaries, inhibition of aerobic and anaerobic bacteria. 63, 64 According to the selection criteria used, we selected one clinical, randomised and controlled trial. performed five times a week for 6 weeks. A significant difference was found in the treated group when compared to the untreated group in relation to salivary consistency and xerostomia.
There is no enough evidence to recommend hyperbaric oxygen therapy for treating radiation-induced xerostomia. Moreover, it is important to consider that the need for frequent sessions and use of specific equipment make it a very pricy treatment.
| D ISCUSS I ON
Salivary dysfunctions affect a large part of the world population. Another salivary stimulant discussed in the present review was acupuncture. The studies suggest its efficacy in combating xerostomia, but it is necessary that residual functional glandular capacity still exists for salivary secretion to increase. [31] [32] [33] [34] According to the results of the clinical trials, this therapeutic modality was classified as promising for the treatment of salivary hypofunction, but more controlled clinical trials using sham acupuncture are required. Other therapies that could be classified as promising are gene therapy 62 and stem cell therapy 53, 54 ; however, there are still no controlled clinical studies supporting this evidence. Using stem cell transplantation derived from adipose tissue, an increase of more than 70% was obtained in salivary production in irradiated animals. 53 Such cells can be obtained from oneself, processed and transplanted directly into the affected salivary gland. However, the procedures require highly complex techniques and high cost. Gene therapy may be a therapeutic option for salivary hypofunction in the future. The progress in gene therapy for patients with Sjögren's syndrome has been slow, because of the lack of understanding of the disease etiopathogenesis. Gene therapy for radiation-damaged salivary glands has shown promise. 66 Salivary substitutes such as HEC, PGM and xanthan gum are supposed to promote a temporary xerostomia relief. 22, 24, 25 However, there are few controlled clinical trials investigating their effects.
There is no scientific evidence that these products have effect on reducing the symptoms of xerostomia once they do not assist in the salivary production. Salivary stimulants based on citric acid 26 and malic acid 23, 27 have been suggested for the management of salivary hypofunction when functional glandular tissue is still present.
They induce acidification in the oral environment, thereby increase salivary production and promote a temporary xerostomia relief.
However, the controlled clinical trials investigating their effects have follow-up times short. In addition, acid products have several side effects such as the risk of dental hypersensitivity and erosion, and dental caries. Therefore, these acidic products cannot be recommended in clinical practice and were classified as therapeutic modalities with weak evidence of beneficial effect on salivary dysfunction.
Understanding the mechanisms of action of the therapeutic modalities for salivary hypofunction, as well as its adverse effects, is fundamental in the selection of the best treatment for the patient.
There is no a gold standard for the treatment of xerostomia and hyposalivation. Several factors such as residual glandular capacity, individual access to treatment and cost-effectiveness should be taken into consideration. None of the therapeutic modalities presented in our paper had an effect on re-establishing glandular function.
Further research on stem cell therapy and gene therapy is required to move extend our knowledge of managing hyposalivation.
| CON CLUS IONS
• In most clinical trials, the number of participants was low and the follow-up short.
• Pilocarpine and cevimeline have the strongest evidence of beneficial effect on salivary hypofunction.
• Citric and malic acids increase salivary flow but also increase the risk of erosion and dental caries.
• There are no controlled clinical trials supporting the efficacy of acupuncture, stem cell therapy and gene therapy on salivary dysfunction, although clinical observations suggest a promising effect.
• There is no evidence supporting salivary substitutes, chewing gum, bethanechol or hyperbaric oxygen on the treatment of salivary hypofunction. 
